Form 4: Jupiter Neurosciences CFO Receives Significant Equity Compensation

Jupiter Neurosciences, Inc.'s CFO and Secretary, Saleem Elmasri, has reported the vesting of restricted stock units and the grant of new stock options as part of his compensation.

Summary

• Saleem Elmasri, CFO and Secretary of Jupiter Neurosciences, Inc. (JUNS), acquired 66,293 shares of common stock on June 2, 2025, through the vesting of restricted stock units (RSUs).
• These RSUs vested upon the expiration of the lock-up period following the Issuer's initial public offering, resulting in a beneficial ownership of 66,239 common shares.
• Additionally, on July 2, 2025, Mr. Elmasri was granted 102,128 stock options under the Issuer's 2023 Equity Incentive Plan.
• These options, with an exercise price of $1.19 per share, were awarded as a discretionary bonus for services rendered during fiscal year 2024.
• The stock options will vest in three equal installments over a three-year period, commencing on July 2, 2025, and have an expiration date of July 1, 2035.

Sentiment

Score: 6

Explanation: The document reports routine executive compensation events (RSU vesting and option grant), which are generally positive for management alignment but do not indicate significant new operational or financial developments. It reflects standard corporate practice.

Positives

• The vesting of restricted stock units and the grant of stock options align the interests of the CFO with those of shareholders, as his compensation is tied to the company's equity performance.
• The equity grants serve as a retention mechanism for key management personnel, ensuring continuity and commitment.
• The discretionary bonus in the form of stock options acknowledges and rewards past performance, potentially motivating continued strong contributions.

Future Outlook

The granted stock options will vest in three equal installments over a three-year period, commencing on July 2, 2025, indicating future equity compensation milestones for the CFO.

Management Comments

• The restricted stock units vested on the expiration of the lock-up period for the Issuer's initial public offering.
• The stock options were granted under the Issuer's 2023 Equity Incentive Plan as a discretionary bonus for services rendered during fiscal 2024.

Industry Context

The grant of restricted stock units and stock options is a standard practice in the biotechnology and pharmaceutical industries for executive compensation, aiming to attract, retain, and incentivize key talent by aligning their financial interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• The use of restricted stock units and stock options as components of executive compensation is a common practice across the biotechnology and pharmaceutical sectors, consistent with global benchmarks for incentivizing management.
• Specific comparisons of the volume or value of these grants to comparable companies would require detailed compensation peer group analysis, which is not provided in this filing. However, the structure of vesting over time for options is typical.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the CFO's interests with shareholder value creation, as his compensation is directly tied to the company's stock performance.
• Employees: The discretionary bonus in the form of options may signal a commitment to rewarding performance, potentially influencing overall employee morale and retention strategies.

Next Steps

• Future vesting installments of the 102,128 stock options will occur over the next three years, starting July 2, 2025.

Key Dates

Keywords

Jupiter Neurosciences, JUNS, SEC Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, Stock Options, Equity Incentive Plan, CFO, Saleem Elmasri, Corporate Governance